Stephens initiated coverage of Apogee Therapeutics (APGE) with an Overweight rating and $95 price target Lead asset APG777 is advancing in atopic dermatitis and asthma, with potential expansion across other I&I indications, notes the analyst, who contends that current data in AD has demonstrated “compelling efficacy and safety.” The firm views APG777 as positioned as “a credible competitor” to Dupixent, which it calls “the multi-billion-dollar benchmark in Type 2 inflammation.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/10/2025, According to Top Analysts
- Apogee Therapeutics initiated with a Buy at Deutsche Bank
- Buy Rating for Apogee Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook
- Apogee Therapeutics Reports Q3 2025 Financial Progress
- Positive Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trials and Strategic Advancements